A group of scientists have developed a new diagnostic procedure for prostate cancer. The procedure is being tested and has been found to be extremely effective. The scientists have discovered that the testing procedure also has efficacy as a treatment and that most prostate cancers can be slowed or eradicated through this treatment.
Our initial analysis indicates this new procedure is much more efficient and effective than current detection or treatment methods. This technology will require a substantial investment of time, money and management to get it to market but its potential is enormous.
In proceeding with the acquisition of this technology, we would require personnel familiar with the procedural techniques for expediting this through the medical and FDA/HPFB approval process. Securing appropriate personnel to participate in this venture, would be essential to enable Solara to license or purchase the technology from the current ownership group.